Contents

Search

repotrectinib (Augtyro)

Indications: - treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer - all NTRK gene fusion+ solid tumors [1] Dosage: - 160 mg PO QD for 14 days - increase to 160 mg PO BID, with or without food. Capsules: 40 mg Adverse effects: - > 20% - dizziness, dysgeusia, peripheral neuropathy, constipation, dyspnea, ataxia, fatigue, cognitive disorders, muscle weakness Drug interactions: - strong & moderate CYP3A inhibitors: avoid concurrent use - P-glucoprotein inhibitors: avoid concurrent use - strong & moderate CYP3A inducers: avoid concurrent use - hormonal contraceptives: avoid concurrent use Mechanism of action: - inhibits ROS1 & tropomyosin receptor tyrosine kinases TRKA, TRKB, & TRKC

General

small inhibitory antineoplastic agent (ib drug)

Database Correlations

PUBCHEM cid=135565923

References

  1. Alexander Otto M FDA Expands Repotrectinib Label to All NTRK Gene Fusion+ Solid Tumors. Medscape. June 13, 2024 https://www.medscape.com/viewarticle/fda-expands-repotrectinib-label-all-ntrk-gene-fusion-solid-2024a1000b3q
  2. HIGHLIGHTS OF PRESCRIBING INFORMATION Augtyro (repotrectinib) capsules, for oral use https://packageinserts.bms.com/pi/pi_augtyro.pdf